TSND-201

Transcend Therapeutics, founded in 2021, is a clinical-stage, neuroscience-focused company developing rapid-acting treatments for neuropsychiatric diseases. Our mission is to develop new drugs for the millions of people for whom current psychiatric medicines have not worked. We are developing TSND-201 (methylone) as a rapid-acting and durable treatment for Post-Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and other Central Nervous System (CNS) indications.

We’ve published a clinical case series in which methylone demonstrated robust responses in patients with PTSD[1], most of whom would be considered severely ill and had failed prior treatment. And, unlike first-generation psychedelics and entactogens such as psilocybin or MDMA, we have data suggesting that methylone’s effects would be unchanged for patients taking antidepressants (e.g., Prozac and other SSRIs) for mental illness – making it a potentially viable option for a much greater number of people. PTSD and depression have a huge unmet medical need in the U.S. and abroad. Of the approximately 12 million patients with PTSD[2] and 26 million patients with major depressive disorder[3] in the U.S. alone, approximately 70% are prescribed antidepressants[4],[5]. In addition, unlike classic psychedelics, methylone is not hallucinogenic, has short-acting and mild psychological effects, and could require less clinician time for administration, making it better suited to integrate into our existing medical system.